Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study

Stroke

Volumn 30, Issue 12, 1999, Pages 2547-2553

  Feinberg, William M ^a   Pearce, Lesly A ^b   Hart, Robert G ^c,f   Cushman, Mary ^d   Cornell, Elaine S ^d   Lip, Gregory Y H ^e   Bovill, Edwin G ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Axio Research Corporation   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e CITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atrial fibrillation; Coagulation; Fibrinogen; Platelet activation; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; PROTHROMBIN; THROMBIN;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

EID: 0032749688     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.12.2547     Document Type: Article

References (37)

1. Stroke Prevention in Atrial Fibrillation Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Intern Med. 1998;128: 639-647.
2. Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederrich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75: 219-223.
3. Lip GYH, Lip PL, Zarifis J, Watson RDS, Bareford D, Lowe GDO, Beevers DG. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation. 1996; 94:425-431.
4. Sohara H, Amitani S, Curose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106-112.
5. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke. 1990;21:47-51.
6. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation. Am Heart J. 1996;131: 724-730.
7. Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y, Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 1997;17:3191-3195.
8. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C, Morishita E, Yamazaki M, Shibata K, Mizuhashi K, Mifune J, Matsuda E. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469-473.
9. Pongratz G, Brandt-Pohlmann M, Henneke K-H, Pohle C, Zink D, Gehling G, Bachmann K. Platelet activation in embolic and pre-embolic status of patients with nonrheumatic atrial fibrillation. Chest. 1997;111: 929-933.
10. Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ. 1997;157:673-681.
11. Feinberg WM, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Hart RG, Bovill EG. Relationship between prothrombin activation fragment 1.2 and international normalized ratio in patients with atrial fibrillation. Stroke. 1997;28:1101-1106.
12. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the role of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
13. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;5:341-353.
14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
15. Stroke Prevention in Atrial Fibrillation Investigators. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA. 1998;279:1273-1277.
16. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32-36.
17. Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, Tracy RP. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16: 1163-1169.
18. Clauss A. Eine gerinnungs-physiologische Schnell-methode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237.
19. Geffken DF, Keating FG, Kennedy MH, Cornell ES, Bovill EG, Tracy RP. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med. 1994;118: 1106-1109.
20. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998;79:912-915.
21. Hursting MJ, Stad AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem. 1993;39:683-686.
22. Greenberg CS, Hursting MJ, Macik DG, Ortel TL, Kane WH, Moore BM. Evaluation of pre-analytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem. 1994;40:1962-1969.
23. Bauer KA, Weiss LM, Sparrow D, Vokonas DS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest. 1987;80:1527-1534.
24. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. Br J Haematol. 1997;97:775-784.
25. Rugman FP, Jenkins JA, Duguid JK, Bolton Maggs P, Hay CRM. Prothrombin fragment 1+2: correlations with cardiovascular risk factors. Blood Coagul Fibrinolysis. 1994;5:335-340.
26. Miller GJ, Bauer KA, Barzeger S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. Effects of quality and timing of venipuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82-86.
27. Yamamoto K, Ikeda U, Fukazawa H, Shimada K. Effects of aspirin on status of thrombin generation in atrial fibrillation. Am J Cardiol. 1996; 77:528-530.
28. Carrieri P, Orefice G, Indaco A. No effect of acetylsalicylic acid on B-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischemic attacks. Stroke. 1986;17:1153-1155.
29. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke. 1985;16:643-647.
30. Tse HF, Lau CP, Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol. 1997;30:1813-1818.
31. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma β-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J. 1986;27:481-487.
32. Nguyen ND, Ghaddar H, Stinson V, Chambliss LE, Wu KK. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost. 1995;73:256-260.
33. Gonzales F, Manas M, Seiquer I, Quiles J, Mataix FJ, Huertas JR, Martinez-Victoria E. Blood platelet function in healthy individuals of different ages. J Sports Med Phys Fitness. 1996;36:112-116.
34. Parizek M, Kubisz P. Platelet reactivity: a contribution to age-dependence studies. Folia Haematol. 1988;115:621-627.
35. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Stroke. 1999;30:1223-1229.
36. Minar E, Ehringer H, Jung M, Koppensteiner R, Stumpflen A. Lack of influence of low-dose acetylsalicylic acid (100 mg daily) on platelet survival time, β-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive disease. Thromb Res. 1988;52:219-226.
37. Eikelboom J, Thorn J, Van Bockxmeer F, Baker R. Does activated protein C resistance increase the risk of systemic embolism in non-rheumatic atrial fibrillation? Aust N Z J Med. 1996;26:243-244.